SARS-CoV-2 (COVID-19) Spike G142D Δ143-145VYY Peptide (Omicron)-其他肽-深圳欣博盛生物科技有限公司

首页产品中心其他肽

SARS-CoV-2 (COVID-19) Spike G142D Δ143-145VYY Peptide (Omicron)

品牌：ProSci LLC

官网链接

说明书

折扣/货期

货号：9793P

规格：0.05 mg

目录价：￥1740.375

产品详情

* 以下信息仅供参考，详情请以原厂网站为准

产品名称:

SARS-CoV-2 (COVID-19) Spike G142D Δ143-145VYY Peptide (Omicron)

别名:

SARS-CoV-2 Omicron Variant Spike antibody: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Surface Glycoprotein, Spike protein, Omicron Variant

实验应用:

Blocking

产品浓度:

200 ug/mL

保存温度:

Store SARS-CoV-2 (COVID-19) Spike G142D Δ143-145VYY Peptide (Omicron) at -20˚C, stable for one year.

运输温度:

Blue Ice

产品形式:

Liquid

存储溶液:

PBS pH 7.2 (10 mM NaH2PO4, 10 mM Na2HPO4, 130 mM NaCl) containing 0.1% bovine serum albumin and 0.02% sodium azide

产地:

美国

生产商:

Prosci

功能与背景:

SARS-CoV-2 Omicron variant, a variant of concern (VOC), known as B.1.1.529, was detected in South Africa at the end of November in 2021. However, it rapidly spread all over of the world and now it is the dominant variant in the world, which account for more than 90% of the new cases. Omicron variant spike protein carries around 30 amino acid changes, including mutations, deletions and insertions, 15 of which are in the receptor binding domain (RBD). Enhanced transmission of the Omicron variant was observed globally, which is at least 70 times more contagious than the other variants. The Omicron variant affects the effectiveness of COVID-19 vaccine and is resistant to neutralization (monoclonal antibody treatments) to a large extent.

Accession #:

QHD43416

您可能感兴趣的产品

In vivo Collagen Hybridizing Peptide, sulfo-Cy7.5 Conjugate

货号：INVIVOKIT7.5

In vivo Collagen Hybridizing Peptide, sulfo-Cy7.5 Conjugate

货号：INVIVOCTL7.5

In vivo Collagen Hybridizing Peptide, sulfo-Cy7.5 Conjugate

货号：INVIVOTGT7.5

Collagen Hybridizing Peptide, Cy3 Conjugate

货号：RED60CTL

Collagen Hybridizing Peptide, Cy3 Conjugate